Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 10 versus DRAXIMAGE MDP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 10 versus DRAXIMAGE MDP 25.
DRAXIMAGE MDP-10 vs DRAXIMAGE MDP-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in areas of bone turnover, binding via chemisorption to hydroxyapatite crystals, allowing scintigraphic imaging of skeletal lesions.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
555-1110 MBq (15-30 mCi) intravenously for skeletal imaging; administered 2-3 hours before imaging.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
None Documented
None Documented
Terminal elimination half-life: 2.5 hours (range 2-3 hours); clinically, allows rapid imaging post-injection.
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Renal: 95% within 6 hours; biliary/fecal: <5%.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical